Buy, hold, sell: Resmed, Goodman Group, CBA shares

Detailed summary

We review three fresh buy, hold, and sell calls from John Athanasiou at Red Leaf Securities. The post Buy, hold, sell: Resmed, Goodman Group, CBA shares appeared first on The…

S&P/ASX 200 Index (ASX: XJO) shares are down 0.8% to 9,072.8 points on Friday.

On The Bull, John Athanasiou from Red Leaf Securities explains his latest ratings on three ASX 200 shares.

The Resmed share price is $34.99, down 1.5% today and down 9% over 12 months.

Resmed's respiratory devices are market leaders for the treatment of sleep apnoea.

The sleep apnoea market worldwide is huge, but in recent years investors have been concerned that GLP-1 obesity and diabetes medicines like Ozempic would reduce that market given sleep apnoea is common in patients with obesity.

The height of that concern was seen in late 2023 when the Resmed share price fell to the early $20-range. Resmed did a lot of in-house research to establish how big the GLP-1 threat was and found that the new drugs were actually helping to drive new sales.

Resmed shares have not been back in the low-$20 range since that time, and today, Athanasiou gives the healthcare share a buy rating.

The Goodman Group share price is $28.90, down 1.9% today and down 3% over 12 months.

Goodman is a global industrial property investment and development group.

Opening of the article, excerpted from The Motley Fool Australia. To read the rest, open the article on the publisher's site.